Natera's Prospera Lung Transplant Assessment Test Granted Medicare Coverage
Portfolio Pulse from Happy Mohamed
Natera, Inc. (NASDAQ:NTRA) has received confirmation that its Prospera Lung transplant assessment test has met coverage requirements from the Centers for Medicare & Medicaid Services' (CMS) Molecular Diagnostics Services Program (MolDX). The test, which helps detect acute rejection in lung transplant patients, will be covered under the existing Medicare Local Coverage Determination for Molecular Testing for Solid Organ Allograft Rejection. The decision is expected to increase access to the test, which has already been used by nearly 50% of the top 50 transplant centers.
August 16, 2023 | 1:09 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Natera's Prospera Lung test has received Medicare coverage, which could increase its usage among lung transplant patients and potentially boost the company's revenues.
The news of Medicare coverage for Natera's Prospera Lung test is directly relevant to the company and could have a positive impact on its stock. The coverage could lead to increased usage of the test, particularly as it has already been used by nearly 50% of the top 50 transplant centers. This could potentially lead to increased revenues for Natera.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100